European Parliament 15 June 2001, WRITTEN QUESTION E-1749/01 by José García-Margallo y Marfil (PPE-DE) to the Commission. Communication on intra-Community investment.

AMVTN is now developing trial sites based on earlier extensive epidemiological ground-work carried out by three African countries with support from the Community and Member States. The current effort to establish itself as a legal body under Tanzanian law is an important prerequisite to play an active role in supporting the expansion of clinical trials in the region.